Concomitant expression of several peptide receptors in neuroendocrine tumours: Molecular basis for in vivo multireceptor tumour targeting
Reubi JC, Waser B. Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging 2003;30:781-93.
Preclinical evaluation of new and highly potent analogues of octreotide for predictive imaging and targeted radiotherapy
Ginj M, Chen J, Walter MA, Eltschinger V, Reubi JC, Maecke HR. Preclinical evaluation of new and highly potent analogues of octreotide for predictive imaging and targeted radiotherapy. Clin Cancer Res 2005;11:1136-45.
Design, synthesis, and biological evaluation of somatostatin-based radiopeptides
Ginj M, Schmitt JS, Waser B, Reubi JC, de Jong M, Schulz S et al. Design, synthesis, and biological evaluation of somatostatin-based radiopeptides. Chem Biol 2006;13:1081-90.
Comparison of the pharmacokinetics of (68)Ga-DOTATOC and [(18)F]FDG in patients with metastatic neuroendocrine tumours scheduled for (90)Y-DOTATOC therapy
Koukouraki S, Strauss LG, Georgoulias V, Eisenhut M, Haberkorn U, Dimitrakopoulou-Strauss A. Comparison of the pharmacokinetics of (68)Ga-DOTATOC and [(18)F]FDG in patients with metastatic neuroendocrine tumours scheduled for (90)Y-DOTATOC therapy. Eur J Nucl Med Mol Imaging 2006;33:1115-22.
Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands
Reubi JC, Waser B, Schaer JC, Laissue JA. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med 2001;28:836-46.
Somatostatin receptor scintigraphy: Its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas: a prospective study
Gibril F, Reynolds JC, Doppman JL, Chen CC, Venzon DJ, Termanini B et al. Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas: a prospective study. Ann Intern Med 1996;125:24-6.
de Jong M, Bakker WH, Krenning EP, Breeman WA, van der Pluijm, Bernard PF et al. Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0,D-Phel,Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy. Eur J Nucl Med 1997;24:368-71.
de Jong M, Bakker WH, Krenning EP, Breeman WA, van der Pluijm, Bernard PF et al. Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0,D-Phel,Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy. Eur J Nucl Med 1997;24:368-71.
25
0032725922
Yttrium-90-DOTATOC: First clinical results
Otte A, Herrmann R, Heppeler A, Behe M, Jermann E, Powell P et al. Yttrium-90-DOTATOC: first clinical results. Eur J Nucl Med 1999;26:1439-47.
Yttrium-90-labelled somatostatin-analogue for cancer treatment
Otte A, Mueller-Brand J, Dellas S, Nitzsche E, Herrmann R, Maecke H. Yttrium-90-labelled somatostatin-analogue for cancer treatment. Lancet 1998;351:417-8.
Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use
Reubi J, Schaer J, Waser B, Wenger S, Heppeler A, Schmitt J et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 2000;27:273-82.
DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labeling with various radiometals
Wild D, Schmitt JS, Ginj M, Macke HR, Bernard BF, Krenning E et al. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labeling with various radiometals. Eur J Eur J Nucl Med 2003;30:1338-47.
Effectiveness and limits of preoperative imaging studies for the localisation of pheochromocytomas and paragangliomas: A review of 282 cases
Jalil ND, Pattou FN, Combernale F, Chapuis Y, Henry JF, Peix JL et al. Effectiveness and limits of preoperative imaging studies for the localisation of pheochromocytomas and paragangliomas: a review of 282 cases. Eur J Surg 1998;164:23-8.
Uptake of iodine-123 MIBG by pheochrornocytomas, paragangliomas, and neuroblastomas: A histopathological comparison
Bomanji J, Levison DA, Flatman WD, Horne T, Bouloux PM, Ross G et al. Uptake of iodine-123 MIBG by pheochrornocytomas, paragangliomas, and neuroblastomas: a histopathological comparison. J Nucl Med 1987; 28:973-8.
Pheochrornocytoma and the normal adrenal medulla: Improved visualization with I-123 MIBG scintigraphy
Lynn MD, Shapiro B, Sisson JC, Beierwaltes WH, Meyers LJ, Ackerman R et al. Pheochrornocytoma and the normal adrenal medulla: improved visualization with I-123 MIBG scintigraphy. Radiology 1985;155:789-92.
The efficacy of iodine-123-MIBG as a screening test for pheochromocytorna
Mozley PD, Kim CK, Moshin J, Gosfield E, Alavi A. The efficacy of iodine-123-MIBG as a screening test for pheochromocytorna. J Nucl Med 1994;35:1138-44.
van der Harst E, de Herder WW, Bruining HA, Bonjer HJ, de Krijger RR, Lamberts SWJ et al. 123[I]Metaiodobenzylguanidine and 111[In]octreotide uptake in benign and malignant pheochromocytomas. J Clin Endocrinol Metab 2001;86:685-93.
van der Harst E, de Herder WW, Bruining HA, Bonjer HJ, de Krijger RR, Lamberts SWJ et al. 123[I]Metaiodobenzylguanidine and 111[In]octreotide uptake in benign and malignant pheochromocytomas. J Clin Endocrinol Metab 2001;86:685-93.
37
0030221078
The role of radiolabeled somatostatin analogs in adrenal imaging
Maurea S, Lastoria S, Caraco, C, Klain M, varrella P, Acampa W et al. The role of radiolabeled somatostatin analogs in adrenal imaging. Nucl Med Biol 1996;23:677-80.
Detection of malignant pheochromocytoma tumor sites by 111-In-octreotide scintigraphy
Steinert H, Lehnert H, Bockisch A, Beyer J, Hahn K. Detection of malignant pheochromocytoma tumor sites by 111-In-octreotide scintigraphy. Eur J Nucl Med 1993;20:843.
Comparison of labeled MIBG and somatostatin analogs in imaging neuroendocrine tumors
Lastoria S, Maurea S, Vergara E, Acampa W, Varrella P, Klain M et al. Comparison of labeled MIBG and somatostatin analogs in imaging neuroendocrine tumors. Q J Nucl Med 1995;39:145-9.
Comparison of radiolabeled octreotide and meta-iodobenzylguariidine (MIBG) scintigruphy in malignant pheochromocytoma
Tenenbaum F, Lumbroso J, Schlumberger M, Mure A, Plouin PF, Caillou B et al. Comparison of radiolabeled octreotide and meta-iodobenzylguariidine (MIBG) scintigruphy in malignant pheochromocytoma. J Nucl Med 1995;36:1-6.
Experience with indium-111 and yttrium-90-labeted somatostatin analogs
Virgolini I, Traub T, Novotny C, Leimer M, Fuger B, Li SR et al. Experience with indium-111 and yttrium-90-labeted somatostatin analogs. Curr Pharm Des 2002;8:1781-807.
Somatostatin receptor scintigraphy in the differential diagnosis of meningioma
Bohuslavizki KH, Brenner W, Braunsdorf WE, Behnke A, Tinnemeyer S, Hugo HH et al. Somatostatin receptor scintigraphy in the differential diagnosis of meningioma. Nucl Med Commun 1996;17:302-10.
Quantitative assessment of SSTR2 expression in patients with non-small cell lung cancer using(68)Ga- DOTATOC PET and comparison with (18)F-FDG PET
Dimitrakopoulou-Strauss A, Georgoulias V, Eisenhut M, Herth F, Koukouraki S, Macke HR et al. Quantitative assessment of SSTR2 expression in patients with non-small cell lung cancer using(68)Ga- DOTATOC PET and comparison with (18)F-FDG PET. Eur J Nucl Med Mol Imaging 2006;33:823-30.
